Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RBD 4059

X
Drug Profile

RBD 4059

Alternative Names: RBD-4059

Latest Information Update: 28 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Ribo Life Science
  • Class Amino sugars; Antithrombotics; Drug conjugates; Small interfering RNA; Vascular disorder therapies
  • Mechanism of Action Factor XI expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary artery disease
  • Phase I Thromboembolism

Most Recent Events

  • 30 Aug 2024 Pharmacokinetics, pharmacodynamics and adverse event data from a phase I trial in Thromboembolism presented at the Annual Congress of the European Society of Cardiology (ESC-2024)
  • 28 Aug 2024 Phase-II clinical trials in Coronary artery disease in Sweden (SC) (NCT06717074)
  • 25 Aug 2023 Pharmacodynamics and adverse events data from a preclinical trial in thromboembolism presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology (ESC-Card-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top